DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong-Gun | ko |
dc.contributor.author | Kim, Uijin | ko |
dc.contributor.author | Park, In Ho | ko |
dc.contributor.author | Ryu, Bumhan | ko |
dc.contributor.author | Yoo, Youngki | ko |
dc.contributor.author | Cha, Jeong Seok | ko |
dc.contributor.author | Yoon, Ga-Yeon | ko |
dc.contributor.author | Kim, Sung-Hee | ko |
dc.contributor.author | Oh, Heeju | ko |
dc.contributor.author | Seo, Jun-Young | ko |
dc.contributor.author | Nam, Ki Taek | ko |
dc.contributor.author | Seong, Je Kyung | ko |
dc.contributor.author | Shin, Jeon-Soo | ko |
dc.contributor.author | Cho, Hyun-Soo | ko |
dc.contributor.author | Kim, Hak-Sung | ko |
dc.date.accessioned | 2024-01-02T05:01:26Z | - |
dc.date.available | 2024-01-02T05:01:26Z | - |
dc.date.created | 2024-01-02 | - |
dc.date.issued | 2023-12 | - |
dc.identifier.citation | ANTIVIRAL RESEARCH, v.220 | - |
dc.identifier.issn | 0166-3542 | - |
dc.identifier.uri | http://hdl.handle.net/10203/317161 | - |
dc.description.abstract | Coronavirus Disease 2019 (COVID-19) pandemic is severely impacting the world, and tremendous efforts have been made to deal with it. Despite many advances in vaccines and therapeutics, severe acute respiratory syn-drome coronavirus 2 (SARS-CoV-2) variants remains an intractable challenge. We present a bivalent Receptor Binding Domain (RBD)-specific synthetic antibody, specific for the RBD of wild-type (lineage A), developed from a non-antibody protein scaffold composed of LRR (Leucine-rich repeat) modules through phage display. We further reinforced the unique feature of the synthetic antibody by constructing a tandem dimeric form. The resulting bivalent form showed a broader neutralizing activity against the variants. The in vivo neutralizing efficacy of the bivalent synthetic antibody was confirmed using a human ACE2-expressing mouse model that significantly alleviated viral titer and lung infection. The present approach can be used to develop a synthetic antibody showing a broader neutralizing activity against a multitude of SARS-CoV-2 variants. | - |
dc.language | English | - |
dc.publisher | ELSEVIER | - |
dc.title | A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants | - |
dc.type | Article | - |
dc.identifier.wosid | 001126983800001 | - |
dc.identifier.scopusid | 2-s2.0-85178064019 | - |
dc.type.rims | ART | - |
dc.citation.volume | 220 | - |
dc.citation.publicationname | ANTIVIRAL RESEARCH | - |
dc.identifier.doi | 10.1016/j.antiviral.2023.105738 | - |
dc.contributor.localauthor | Kim, Hak-Sung | - |
dc.contributor.nonIdAuthor | Kim, Uijin | - |
dc.contributor.nonIdAuthor | Park, In Ho | - |
dc.contributor.nonIdAuthor | Ryu, Bumhan | - |
dc.contributor.nonIdAuthor | Yoo, Youngki | - |
dc.contributor.nonIdAuthor | Cha, Jeong Seok | - |
dc.contributor.nonIdAuthor | Yoon, Ga-Yeon | - |
dc.contributor.nonIdAuthor | Kim, Sung-Hee | - |
dc.contributor.nonIdAuthor | Oh, Heeju | - |
dc.contributor.nonIdAuthor | Seo, Jun-Young | - |
dc.contributor.nonIdAuthor | Nam, Ki Taek | - |
dc.contributor.nonIdAuthor | Seong, Je Kyung | - |
dc.contributor.nonIdAuthor | Shin, Jeon-Soo | - |
dc.contributor.nonIdAuthor | Cho, Hyun-Soo | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Severe acute respiratory syndrome coronavirus | - |
dc.subject.keywordAuthor | 2 (SARS-CoV-2) | - |
dc.subject.keywordAuthor | Repebody | - |
dc.subject.keywordAuthor | Synthetic antibody | - |
dc.subject.keywordAuthor | Receptor binding domain (RBD) variant | - |
dc.subject.keywordAuthor | Cryo-EM | - |
dc.subject.keywordPlus | RECEPTOR-BINDING DOMAIN | - |
dc.subject.keywordPlus | PROTEIN BINDER | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | AFFINITY | - |
dc.subject.keywordPlus | ACE2 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.